Phuturdex › Diseases › Squamous cell carcinoma
Drugs in development · updated 30 October 2026
Squamous cell carcinoma: drugs in development
As of 30 October 2026 there are 71 active clinical trials (recruiting or ongoing, phases I–III) on 72 drugs for squamous cell carcinoma. 29 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Ateganosine6-Thio-2'-Deoxyguanosine | III | 2 | NCT06908304 |
| INBRX-106 | II–III | 2 | NCT06295731 |
| Ficlatuzumab | III | 1 | NCT06064877 |
| JNJ-90301900 | III | 1 | NCT04892173 |
| NicotinamideNicotinomide | III | 1 | NCT05955924 |
| Ficerafusp alfaBCA101 | I–II | 2 | NCT07552558 |
| Tiragolumab | II | 2 | NCT03708224 |
| AnlotinibAL3818, Anrotinib | II | 1 | NCT05252078 |
| ATRN-119 | I–II | 1 | NCT07578467 |
| AZD6750 | I–II | 1 | NCT07115043 |
| Bavituximab | II | 1 | NCT04150900 |
| BenmelstobartTQB2450 | II | 1 | NCT05252078 |
| FianlimabREGN3767 | II | 1 | NCT07346196 |
| HMBD-001 | I–II | 1 | NCT05910827 |
| IDP-001 | I–II | 1 | NCT07602842 |
| IvonescimabAK112 | II | 1 | NCT06814158 |
| Lirilumab | II | 1 | NCT03341936 |
| N17350 | I–II | 1 | NCT07339176 |
| NEO212 Oral Capsule | I–II | 1 | NCT06047379 |
| RilvegostomigAZD2936 | I–II | 1 | NCT07115043 |
| RRx-001 | II | 1 | NCT05966194 |
| T3011 | I–II | 1 | NCT04370587 |
| Tigilanol Tiglate | II | 1 | NCT05608876 |
| Vilastobart | II | 1 | NCT07896811 |
| IL-15 | I | 1 | NCT07631013 |
| LY4050784 | I | 1 | NCT06561685 |
| MQ719 | I | 1 | NCT05859074 |
| Nivo800 | I | 1 | NCT07460765 |
| ZanzalintinibXL092 | I | 1 | NCT06912087 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| PembrolizumabKEYTRUDA, MK-3475 | II–III | 19 | NCT06295731 |
| CisplatinCis Platinum, Cisplatine | II–III | 13 | NCT03952585 |
| CarboplatinCarboplatine, Paraplatin | III | 10 | NCT01706939 |
| CemiplimabREGN2810, Libtayo® | III | 7 | NCT06908304 |
| CetuximabErbitux | III | 7 | NCT04892173 |
| DocetaxelTaxotere, Beizray® | III | 6 | NCT06908304 |
| NivolumabOpdivo, ONO-4538 | II–III | 5 | NCT03952585 |
| GemcitabineGemcitabin, Gemzar | III | 2 | NCT06908304 |
| ImiquimodZyclara®, Aldara® | III | 1 | NCT05212246 |
| Methylene BlueProvayblue® | III | 1 | NCT07311057 |
| VinorelbineNavelbine® | III | 1 | NCT06908304 |
| PaclitaxelTaxol, Paxlitaxel | I–II | 6 | NCT06047379 |
| AtezolizumabTecentriq, MPDL3280A | II | 3 | NCT03708224 |
| ToripalimabJS001, Teripalimab | II | 3 | NCT07214987 |
| CyclophosphamideCyclophosphamid, Cytoxan | II | 2 | NCT02133196 |
Sorted by most advanced phase and number of active trials. Showing 15 of 43 drugs.
All 72 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Head and neck squamous cell carcinoma 321 drugs
- Esophageal squamous cell carcinoma 115 drugs
- Non-small-cell lung carcinoma 726 drugs
- Head and neck neoplasms 184 drugs
- Colorectal neoplasm 534 drugs
- Melanoma 352 drugs
- Triple-negative breast neoplasm 334 drugs
- Uterine cervix neoplasm 224 drugs
- Metastasis 493 drugs
- Esophageal neoplasm 191 drugs
- Ovarian neoplasm 411 drugs
- Stomach neoplasm 340 drugs
Broader categories
- Glandular and epithelial neoplasm 12 drugs
- Squamous cell neoplasm 16 drugs
- Neoplasm 671 drugs
- Carcinoma 137 drugs
- Head and neck neoplasms 184 drugs
- Respiratory disease 57 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D002294 “Carcinoma, Squamous Cell”.